Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by Pfizer" The following 200 pages are in this category, out of approximately 240 total. This list may not reflect recent changes .
Pfizer was founded in 1849 as "Charles Pfizer & Company" by Charles Pfizer and Charles F. Erhart, [5] two cousins who had immigrated to the United States from Ludwigsburg, Germany. The business produced chemical compounds, and was headquartered on Bartlett Street [ 6 ] in Williamsburgh, New York where they produced an antiparasitic called ...
Over a hundred of the 224 drugs mentioned in the Huangdi Neijing – an early Chinese medical text – are herbs. [11] Herbs also commonly featured in the medicine of ancient India, where the principal treatment for diseases was diet. [12] A sample of raw opium. Opioids are among the world's oldest known drugs.
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
G.D. Searle, LLC is a wholly owned subsidiary of Pfizer. [1] It is currently a trademark company and subsidiary of Pfizer, operating in more than 43 countries. It also operates as a distribution trademark for various pharmaceuticals that were developed by G. D. Searle & Company (often referred to as Searle).
Parke-Davis is a subsidiary of the pharmaceutical company Pfizer. Although Parke, Davis & Co. is no longer an independent corporation, it was once America's oldest and largest drug maker, and played an important role in medical history. In 1970 Parke-Davis was acquired by Warner–Lambert, which in turn was acquired by Pfizer in 2000. [2]
The Pfizer-Pharmacia merger lead to major cuts in research activities, including the shut down of Sugen over the course of 2003, with the loss of approximately 350 employees. [1] Pfizer continued the phase 3 trials and development of SU11248, now known as Sutent ( sunitinib ), [ 4 ] leading to Food and Drug Administration approval in January ...
Bococizumab (USAN; [1] development code RN316 [2]) is a drug that was in development by Pfizer targeting PCSK9 to reduce LDL cholesterol. [3] Pfizer withdrew the drug from development in November 2016, determining that it was "not likely to provide value to patients, physicians or shareholders."